BioCentury | Dec 22, 2020
Regulation

Dec. 21-23 Regulatory Quick Takes: positive CHMP opinion for Pfizer-BioNTech COVID-19 vaccine; plus Urovant’s approval, a Feb. 9 adcomm for Keytruda in TNBC, NMPA reviewing a subcutaneous PD-L1, and more

...cancer (TNBC).Urovant wins FDA approval of overactive bladder treatmentFDA approved ADRB3 agonist Gemtesa vibegron from Urovant Sciences Ltd....
BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

...Other) Veklury, remdesivir (GS-5734) Beova, vibegron (KRP-114V, MK-4618, RVT-901, SNV004) LIQ861 NIH Gilead Sciences Inc. Eli Lilly and Co. Incyte Corp. United Biomedical Inc. Urovant Sciences Ltd. Liquidia...
BioCentury | Nov 14, 2020
Product Development

Complete response for Sanofi’s rare anemia candidate; plus Sumitovant-Urovant, C4-Roche, IN8bio and Synendos

Setback for Sanofi rare anemia therapySanofi (Euronext:SAN; NASDAQ:SNY) said late Friday that FDA issued a complete response letter to a BLA for anti-C1s mAb sutimlimab to treat hemolysis in adults with cold agglutinin disease, a rare anemia....
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

...He is succeeded by James D’Arecca, who was SVP, chief accounting officer of Allergan plc. Urovant Sciences Ltd....
...Medical Systems Inc. Akcea Therapeutics Inc. iTeos Therapeutics S.A. Amplyx Pharmaceuticals Inc. Antengene Corp. DalCor Pharma U.K. Ltd. SwanBio Therapeutics Ltd. TherapeuticsMD Inc. Urovant Sciences Ltd....
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...tenure at Bristol Myers Squibb Co. (NYSE:BMY) (see “Architects Behind Celgene Takeout Step Down” ). Urovant Sciences Ltd....
...N.V. CytomX Therapeutics Inc. Recursion Pharmaceuticals Inc. 89bio Inc. Heptares Therapeutics Ltd. Sosei Group Corp. Fusion Pharmaceuticals Inc. Freeline Therapeutics Ltd. Seres Therapeutics Inc. Urovant Sciences Ltd. UroGen...
BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

...FDA reviewing Urovant’s incontinence therapy FDA accepted for review an NDA for Beova vibegron from Urovant Sciences Ltd....
...Programmed cell death 1 ligand 1 VEGF - Vascular endothelial growth factor BioCentury Staff Camrelizumab (INCSHR1210, SHR-1210) NIH AstraZeneca plc Urovant Sciences Ltd. Trevena...
BioCentury | Oct 31, 2019
Company News

Roivant pockets $3B from Dainippon, reveals CF focus of fifth ‘vant’

...companies announced plans for Dainippon to acquire Roivant’s stakes in Myovant Sciences GmbH (NYSE:MYOV) and Urovant Sciences Ltd....
...slipped $0.14 to $9.54. Elizabeth S. Eaton, Staff Writer Roivant Sciences Ltd. Sumitomo Dainippon Pharma Co. Ltd. Myovant Sciences GmbH Urovant Sciences Ltd. Enzyvant...
BioCentury | Sep 6, 2019
Company News

Sumitomo Dainippon to bolster pipeline via deal for women's health, urology, rare disease vants for $3B

...company’s market cap of $6.7 billion to assume Roivant's ownership in Myovant Sciences GmbH (NYSE:MYOV), Urovant Sciences Ltd....
...Inc. Datavant Duke University Enzyvant Sciences GmbH J.P. Morgan Myovant Sciences GmbH Roivant Sciences GmbH Sumitomo Dainippon Pharma Co. Ltd. Takeda Pharmaceutical Co. Ltd. Urovant Sciences Ltd. Adrenergic...
BioCentury | Mar 29, 2019
Clinical News

Velicept's overactive bladder therapy meets in Phase IIb

...in 2012. In addition to Myrbetriq, solabegron may also find itself competing with vibegron from Urovant Sciences Ltd....
BioCentury | Mar 19, 2019
Clinical News

Urovant shares slide on vibegron overactive bladder data

...in the Phase III EMPOWUR trial. The company lost $2.91 (20%) to $11 on Tuesday. Urovant Sciences Ltd....
...both adrenergic receptor β 3 (ADRB3) agonists. Meghan Sullivan, Assistant Editor Beova, vibegron (KRP-114V, MK-4618, RVT-901) Roivant Sciences GmbH Urovant Sciences Ltd. Adrenergic...
Items per page:
1 - 10 of 26
BioCentury | Dec 22, 2020
Regulation

Dec. 21-23 Regulatory Quick Takes: positive CHMP opinion for Pfizer-BioNTech COVID-19 vaccine; plus Urovant’s approval, a Feb. 9 adcomm for Keytruda in TNBC, NMPA reviewing a subcutaneous PD-L1, and more

...cancer (TNBC).Urovant wins FDA approval of overactive bladder treatmentFDA approved ADRB3 agonist Gemtesa vibegron from Urovant Sciences Ltd....
BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

...Other) Veklury, remdesivir (GS-5734) Beova, vibegron (KRP-114V, MK-4618, RVT-901, SNV004) LIQ861 NIH Gilead Sciences Inc. Eli Lilly and Co. Incyte Corp. United Biomedical Inc. Urovant Sciences Ltd. Liquidia...
BioCentury | Nov 14, 2020
Product Development

Complete response for Sanofi’s rare anemia candidate; plus Sumitovant-Urovant, C4-Roche, IN8bio and Synendos

Setback for Sanofi rare anemia therapySanofi (Euronext:SAN; NASDAQ:SNY) said late Friday that FDA issued a complete response letter to a BLA for anti-C1s mAb sutimlimab to treat hemolysis in adults with cold agglutinin disease, a rare anemia....
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

...He is succeeded by James D’Arecca, who was SVP, chief accounting officer of Allergan plc. Urovant Sciences Ltd....
...Medical Systems Inc. Akcea Therapeutics Inc. iTeos Therapeutics S.A. Amplyx Pharmaceuticals Inc. Antengene Corp. DalCor Pharma U.K. Ltd. SwanBio Therapeutics Ltd. TherapeuticsMD Inc. Urovant Sciences Ltd....
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...tenure at Bristol Myers Squibb Co. (NYSE:BMY) (see “Architects Behind Celgene Takeout Step Down” ). Urovant Sciences Ltd....
...N.V. CytomX Therapeutics Inc. Recursion Pharmaceuticals Inc. 89bio Inc. Heptares Therapeutics Ltd. Sosei Group Corp. Fusion Pharmaceuticals Inc. Freeline Therapeutics Ltd. Seres Therapeutics Inc. Urovant Sciences Ltd. UroGen...
BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

...FDA reviewing Urovant’s incontinence therapy FDA accepted for review an NDA for Beova vibegron from Urovant Sciences Ltd....
...Programmed cell death 1 ligand 1 VEGF - Vascular endothelial growth factor BioCentury Staff Camrelizumab (INCSHR1210, SHR-1210) NIH AstraZeneca plc Urovant Sciences Ltd. Trevena...
BioCentury | Oct 31, 2019
Company News

Roivant pockets $3B from Dainippon, reveals CF focus of fifth ‘vant’

...companies announced plans for Dainippon to acquire Roivant’s stakes in Myovant Sciences GmbH (NYSE:MYOV) and Urovant Sciences Ltd....
...slipped $0.14 to $9.54. Elizabeth S. Eaton, Staff Writer Roivant Sciences Ltd. Sumitomo Dainippon Pharma Co. Ltd. Myovant Sciences GmbH Urovant Sciences Ltd. Enzyvant...
BioCentury | Sep 6, 2019
Company News

Sumitomo Dainippon to bolster pipeline via deal for women's health, urology, rare disease vants for $3B

...company’s market cap of $6.7 billion to assume Roivant's ownership in Myovant Sciences GmbH (NYSE:MYOV), Urovant Sciences Ltd....
...Inc. Datavant Duke University Enzyvant Sciences GmbH J.P. Morgan Myovant Sciences GmbH Roivant Sciences GmbH Sumitomo Dainippon Pharma Co. Ltd. Takeda Pharmaceutical Co. Ltd. Urovant Sciences Ltd. Adrenergic...
BioCentury | Mar 29, 2019
Clinical News

Velicept's overactive bladder therapy meets in Phase IIb

...in 2012. In addition to Myrbetriq, solabegron may also find itself competing with vibegron from Urovant Sciences Ltd....
BioCentury | Mar 19, 2019
Clinical News

Urovant shares slide on vibegron overactive bladder data

...in the Phase III EMPOWUR trial. The company lost $2.91 (20%) to $11 on Tuesday. Urovant Sciences Ltd....
...both adrenergic receptor β 3 (ADRB3) agonists. Meghan Sullivan, Assistant Editor Beova, vibegron (KRP-114V, MK-4618, RVT-901) Roivant Sciences GmbH Urovant Sciences Ltd. Adrenergic...
Items per page:
1 - 10 of 26